An exploratory study of the barriers and enablers influencing Industry 4.0 adoption in pharmaceutical manufacturing

Abstract

This study was to investigate both the inhibitors and facilitators of the implementation and successful application of Industry 4.0 technologies in the pharmaceutical industry. Although digital transformation is increasingly playing a strategic role in the manufacturing industry in general, it has not been as fast or as easy to adopt as in other sectors, especially those with a focus on Good Manufacturing Practice (GMP) in regulated pharmaceutical environments. This gap in the understanding of the drivers, the barriers and organisational conditions influencing the process was not well understood from a cross-functional practitioner point of view, and this was the gap that this research addressed. An exploratory qualitative research design was employed that used an interpretivist perspective. Primary data was gathered using five semi structured interviews with participants holding various roles within the Quality Assurance, Quality Control, IT Support, Automation and Production Operations departments of GMP regulated pharmaceutical manufacturing establishments. Purposive sampling has been used to choose the participants for cross functional coverage. The six-phase thematic analysis approach proposed by Braun and Clarke (2006) was used for data analysis. Four main themes were found. Firstly, it was identified that all sites were in a hybrid, mid transitional state, with modern digital platforms working alongside legacy equipment, paper based processes and gaps in integration. Secondly, regulatory and compliance pressures, especially regarding data integrity, was the top motivator for digital investment, in addition to customer expectations, operational efficiency, and talent retention. Thirdly, three types of barriers were identified: regulatory and GMP barriers, organisational barriers, and technological barriers. Thirdly, the most frequently reported enablers were hands-on training quality, substantive cross functional engagement at an early stage, and system reliability. A fifth cross-cutting theme emerged spontaneously and in four of the five interviews: covering the human and cognitive aspects of digital change, including the cumulative cognitive load, the risk of skill erosion among professionals due to increased automation, and the risk of institutional knowledge loss due to aging of experienced professionals. The results demonstrated that the adoption of Industry 4.0 in the pharmaceutical industry is more influenced by the organisational conditions and the quality of governance, rather than by choice of technology alone. Practical suggestions were provided for organisations and suggestions for future research were provided, such as: how to ensure that data integrity compliance is achieved while systems are reliable and how to ensure the preservation of knowledge in transition to new members of the workforce.